Changes to the Code
S. 1836 · SMART Prices Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs
5 changes the bill asks for here, 5 carried out
- Carried out:
by striking
2028, 15 negotiation-eligible drugs
and inserting2028 or a subsequent year, 50 negotiation-eligible drugs
; and - Carried out:
by striking
; and
at the end and inserting a period; and - Carried out:
by striking paragraph (4).
- Carried out:
in subparagraph (A)(ii), by striking
7 years
and inserting3 years
; and - Carried out:
in subparagraph (B)(ii), by striking
11 years
and inserting3 years
.
§ 1320f–1(a)–(b)
Start of § 1320f–1 to (a)(1) unchanged ·
(2) with respect to the initial price applicability year 2027, 15 negotiation-eligible drugs described in subparagraph (A) of subsection (d)(1), but not subparagraph (B) of such subsection, with respect to such year (or, all (if such number is less than 15) such negotiation-eligible drugs with respect to such year);
(3) with respect to the initial price applicability year 2028[inserted: or a subsequent year], [struck: 15][inserted: 50] negotiation-eligible drugs described in subparagraph (A) or (B) of subsection (d)(1) with respect to such year (or, all (if such number is less than 15) such negotiation-eligible drugs with respect to such year)[struck: ; and][inserted: .]
[struck: (4)] [struck: with respect to the initial price applicability year 2029 or a subsequent year, 20 negotiation-eligible drugs described in subparagraph (A) or (B) of subsection (d)(1), with respect to such year (or, all (if such number is less than 20) such negotiation-eligible drugs with respect to such year).]
Subject to subsection (c)(2) and section 1320f–3(f)(5) of this title, each drug published on the list pursuant to the previous sentence and subsection (b)(3) shall be subject to the negotiation process under section 1320f–3 of this title for the negotiation period with respect to such initial price applicability year (and the renegotiation process under such section as applicable for any subsequent year during the applicable price applicability period).
(b) Selection of drugs
(1) In general In carrying out subsection (a), subject to paragraph (2), the Secretary shall, with respect to an initial price applicability year, do the following:
§ 1320f–1(e)Qualifying single source drug(1)–(2)
(b)(1)(A)–(e)(1)(A) unchanged ·
(i) that is approved under section 355(c) of title 21 and is marketed pursuant to such approval;
(ii) for which, as of the selected drug publication date with respect to such initial price applicability year, at least [struck: 7][inserted: 3] years will have elapsed since the date of such approval; and
(iii) that is not the listed drug for any drug that is approved and marketed under section 355(j) of such title.
(B) Biological products A biological product—
(i) that is licensed under section 262(a) of this title and is marketed under section 262 of this title;
(ii) for which, as of the selected drug publication date with respect to such initial price applicability year, at least [struck: 11][inserted: 3] years will have elapsed since the date of such licensure; and
(iii) that is not the reference product for any biological product that is licensed and marketed under section 262(k) of this title.
(2) Treatment of authorized generic drugs
Rest of § 1320f–1 unchanged ·
42 U.S.C. § 1320f–3 Negotiation and renegotiation process
3 changes the bill asks for here, 3 carried out
- Carried out:
in subparagraph (A), by striking
75 percent
and inserting76 percent
; - Carried out:
in subparagraph (B), by striking
65 percent
and inserting55 percent
; and - Carried out:
in subparagraph (C), by striking
40 percent
and inserting30 percent
.
§ 1320f–3(c)Ceiling for maximum fair price(3)–(4)
Start of § 1320f–3 to (c)(2)(B)(ii) unchanged ·
(3) Applicable percent described For purposes of this subsection, the applicable percent described in this paragraph is the following:
(A) Short-monopoly drugs and vaccines With respect to a selected drug (other than an extended-monopoly drug and a long-monopoly drug), [struck: 75][inserted: 76] percent.
(B) Extended-monopoly drugs With respect to an extended-monopoly drug, [struck: 65][inserted: 55] percent.
(C) Long-monopoly drugs With respect to a long-monopoly drug, [struck: 40][inserted: 30] percent.
(4) Extended-monopoly drug defined
(A) In general In this part, subject to subparagraph (B), the term “extended-monopoly drug” means, with respect to an initial price applicability year, a selected drug for which at least 12 years, but fewer than 16 years, have elapsed since the date of approval of such drug under section 355(c) of title 21 or since the date of licensure of such drug under section 262(a) of this title, as applicable.
Rest of § 1320f–3 unchanged ·